Blog
RSS FeedPosted by Michael Wonder on 31 Aug 2025
FDA approval of Leqembi subcutaneous formulation charts path to combination therapies for Alzheimer's disease
29 August 2025 - Subcutaneous delivery increases accessibility and introduces potential for at home administration, following model of diabetes and ...
Posted by Michael Wonder on 21 Jan 2021
Doptelet (avatrombopag) approved in the EU for treatment of ITP
20 January 2021 - Sobi today announced that the European Commission has approved an extension of the indication for Doptelet ...
Posted by Michael Wonder on 21 Jan 2021
With a new president and a new Congress, it's time for Medicare drug price negotiation
20 January 2021 - Since passage of the Medicare Modernization Act in 2003, which prohibited Medicare from negotiating prescription drug prices, ...
Posted by Michael Wonder on 20 Jan 2021
TGA grants additional provisional determination for a COVID-19 vaccine
20 January 2021 - The TGA, part of the Department of Health, has granted a provisional determination to Biocelect (on ...
Posted by Michael Wonder on 20 Jan 2021
U.S. FDA accepts for priority review application for Opdivo (nivolumab) combined with chemotherapy as first-line treatment in metastatic gastric cancer, gastro-oesophageal junction cancer and oesophageal adenocarcinoma
20 January 2021 - U.S. FDA assigned a target action date of 25 May 2021. ...
Posted by Michael Wonder on 20 Jan 2021
Patient involvement in relative effectiveness assessments in the European Network for Health Technology Assessment
20 January 2021 - Patient involvement in the process of producing health technology assessments has become increasingly important. In the ...
Posted by Michael Wonder on 20 Jan 2021
U.S. Food and Drug Administration accepts for priority review application for Opdivo (nivolumab) as adjuvant therapy for patients with resected oesophageal or gastro-oesophageal junction cancer
20 January 2021 - Application based on Phase 3 CheckMate-577 trial, in which Opdivo doubled median disease-free survival versus placebo in ...
Posted by Michael Wonder on 20 Jan 2021
Scottish Health Technologies Group: enhancing patient engagement
20 January 2021 - The Scottish Health Technologies Group provides evidence support and advice to the National Health Service in Scotland ...
Posted by Michael Wonder on 20 Jan 2021
AMA call for mass upscaling of home-made drug manufacture
20 January 2021 - The Australian Medical Association has warned of a shortage of essential medications because of supply chain ...
Posted by Michael Wonder on 20 Jan 2021
The representation of public values in health technology assessment to inform funding decisions: the case of Australia's national funding bodies
18 January 2021 - Historically, Australia has been at the forefront of the application of HTA for assessing the effectiveness and ...
Posted by Michael Wonder on 20 Jan 2021
U.S. FDA approves vericiguat for patients with symptomatic chronic heart failure
20 January 2021 - Vericiguat (Verquvo) is the first soluble guanylate cyclase stimulator to be approved for the treatment of symptomatic ...
Posted by Michael Wonder on 20 Jan 2021
Scotland backs Roche’s Rozlytrek for ROS1 lung cancer
19 January 2021 - The Scottish Medicines Consortium has given a green light to Roche’s Rozlytrek for a rare form ...
Posted by Michael Wonder on 20 Jan 2021
Ontario doctors urge domestic drug manufacturing over fears of pandemic shortage
19 January 2021 - Chronic drug shortages have worsened during pandemic, Ontario Medical Association says. ...
Posted by Michael Wonder on 20 Jan 2021
Is Novavax the dark horse of Australia's COVID-19 vaccines?
19 January 2021 - Experts say early clinical data on Australia's third COVID-19 vaccine, Novavax, is promising enough to suggest ...
Posted by Michael Wonder on 20 Jan 2021
COVID-19 vaccines and equity: some Kiwis may get more effective jabs than other
20 January 2021 - Questions have been raised about whether New Zealanders will have equitable access to COVID-19 vaccines, as ...
Posted by Michael Wonder on 20 Jan 2021
Enhertu approved in the EU for the treatment of HER2 positive metastatic breast cancer
20 January 2021 - Approval based on the DESTINY-Breast01 Phase 2 trial which showed clinically meaningful and durable responses in patients ...